Emergent Biosolutions Stock Beta

EBS Stock

USD 9.85 0.37 3.90%

Emergent Biosolutions fundamentals help investors to digest information that contributes to Emergent Biosolutions' financial success or failures. It also enables traders to predict the movement of Emergent Stock. The fundamental analysis module provides a way to measure Emergent Biosolutions' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Emergent Biosolutions stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Emergent Biosolutions Company Beta Analysis

Emergent Biosolutions' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Beta

Covariance

Variance

More About Beta | All Equity Analysis

Current Emergent Biosolutions Beta

1.57

Most of Emergent Biosolutions' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Emergent Biosolutions is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Emergent Beta Driver Correlations

Understanding the fundamental principles of building solid financial models for Emergent Biosolutions is extremely important. It helps to project a fair market value of Emergent Stock properly, considering its historical fundamentals such as Beta. Since Emergent Biosolutions' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Emergent Biosolutions' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Emergent Biosolutions' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Current Deferred Revenue	Long Term Debt	Short Term Investments	Property Plant Equipment	Deferred Long Term Liab	Treasury Stock	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.95	0.65	0.51	0.6	0.62	0.65	0.92	0.64	0.42	0.7	0.69	0.72	0.88	0.78	0.72	0.75	-0.59	0.87	0.85	0.85	0.14	0.55	0.9	0.22	0.04
Total Stockholder Equity	0.95		0.43	0.55	0.44	0.53	0.46	0.79	0.55	0.26	0.51	0.49	0.74	0.8	0.63	0.63	0.64	-0.46	0.8	0.76	0.75	-0.02	0.44	0.81	0.39	0.14
Net Debt	0.65	0.43		-0.03	0.51	0.53	0.72	0.87	0.38	0.64	0.77	0.73	0.31	0.63	0.92	0.81	0.81	-0.77	0.71	0.72	0.79	0.3	0.43	0.77	-0.4	-0.54
Retained Earnings	0.51	0.55	-0.03		0.65	0.55	0.48	0.32	0.83	0.01	0.5	0.47	0.61	0.42	0.15	-0.03	0.14	-0.04	0.33	0.34	0.21	0.03	0.24	0.47	0.6	0.55
Accounts Payable	0.6	0.44	0.51	0.65		0.8	0.92	0.63	0.91	0.25	0.87	0.92	0.7	0.62	0.67	0.41	0.53	-0.44	0.7	0.63	0.64	0.09	0.59	0.65	0.25	-0.04
Net Receivables	0.62	0.53	0.53	0.55	0.8		0.88	0.6	0.7	-0.04	0.85	0.85	0.7	0.77	0.65	0.35	0.49	-0.25	0.65	0.76	0.62	-0.31	0.17	0.58	0.39	0.06
Good Will	0.65	0.46	0.72	0.48	0.92	0.88		0.74	0.79	0.28	0.98	0.98	0.62	0.73	0.79	0.49	0.63	-0.46	0.72	0.76	0.72	0.03	0.42	0.69	0.1	-0.13
Total Liab	0.92	0.79	0.87	0.32	0.63	0.6	0.74		0.61	0.59	0.78	0.74	0.62	0.84	0.92	0.86	0.87	-0.75	0.88	0.88	0.88	0.24	0.61	0.96	-0.04	-0.29
Total Current Assets	0.64	0.55	0.38	0.83	0.91	0.7	0.79	0.61		0.34	0.76	0.79	0.67	0.55	0.52	0.37	0.46	-0.44	0.64	0.54	0.56	0.19	0.58	0.69	0.28	0.1
Short Term Debt	0.42	0.26	0.64	0.01	0.25	-0.04	0.28	0.59	0.34		0.35	0.35	-0.07	0.07	0.49	0.63	0.47	-0.83	0.47	0.14	0.54	0.85	0.61	0.58	-0.7	-0.41
Intangible Assets	0.7	0.51	0.77	0.5	0.87	0.85	0.98	0.78	0.76	0.35		0.96	0.57	0.74	0.81	0.49	0.66	-0.49	0.7	0.77	0.71	0.11	0.36	0.76	0.06	-0.09
Common Stock	0.69	0.49	0.73	0.47	0.92	0.85	0.98	0.74	0.79	0.35	0.96		0.6	0.7	0.8	0.54	0.65	-0.55	0.79	0.72	0.78	0.12	0.51	0.7	0.06	-0.11
Current Deferred Revenue	0.72	0.74	0.31	0.61	0.7	0.7	0.62	0.62	0.67	-0.07	0.57	0.6		0.78	0.6	0.46	0.55	-0.27	0.71	0.77	0.59	-0.3	0.45	0.68	0.64	0.05
Long Term Debt	0.88	0.8	0.63	0.42	0.62	0.77	0.73	0.84	0.55	0.07	0.74	0.7	0.78		0.77	0.59	0.74	-0.35	0.76	0.98	0.72	-0.21	0.34	0.77	0.41	0.02
Short Term Investments	0.78	0.63	0.92	0.15	0.67	0.65	0.79	0.92	0.52	0.49	0.81	0.8	0.6	0.77		0.86	0.87	-0.77	0.88	0.85	0.89	0.11	0.56	0.88	-0.09	-0.49
Property Plant Equipment	0.72	0.63	0.81	-0.03	0.41	0.35	0.49	0.86	0.37	0.63	0.49	0.54	0.46	0.59	0.86		0.87	-0.91	0.87	0.68	0.89	0.22	0.69	0.8	-0.24	-0.63
Deferred Long Term Liab	0.75	0.64	0.81	0.14	0.53	0.49	0.63	0.87	0.46	0.47	0.66	0.65	0.55	0.74	0.87	0.87		-0.77	0.82	0.81	0.84	0.11	0.53	0.8	-0.06	-0.46
Treasury Stock	-0.59	-0.46	-0.77	-0.04	-0.44	-0.25	-0.46	-0.75	-0.44	-0.83	-0.49	-0.55	-0.27	-0.35	-0.77	-0.91	-0.77		-0.78	-0.45	-0.8	-0.53	-0.75	-0.74	0.45	0.61
Net Tangible Assets	0.87	0.8	0.71	0.33	0.7	0.65	0.72	0.88	0.64	0.47	0.7	0.79	0.71	0.76	0.88	0.87	0.82	-0.78		0.78	0.97	0.11	0.73	0.84	0.08	-0.28
Long Term Debt Total	0.85	0.76	0.72	0.34	0.63	0.76	0.76	0.88	0.54	0.14	0.77	0.72	0.77	0.98	0.85	0.68	0.81	-0.45	0.78		0.76	-0.19	0.38	0.81	0.31	-0.17
Capital Surpluse	0.85	0.75	0.79	0.21	0.64	0.62	0.72	0.88	0.56	0.54	0.71	0.78	0.59	0.72	0.89	0.89	0.84	-0.8	0.97	0.76		0.15	0.65	0.81	-0.08	-0.33
Short Long Term Debt	0.14	-0.02	0.3	0.03	0.09	-0.31	0.03	0.24	0.19	0.85	0.11	0.12	-0.3	-0.21	0.11	0.22	0.11	-0.53	0.11	-0.19	0.15		0.49	0.26	-0.67	-0.11
Cash And Equivalents	0.55	0.44	0.43	0.24	0.59	0.17	0.42	0.61	0.58	0.61	0.36	0.51	0.45	0.34	0.56	0.69	0.53	-0.75	0.73	0.38	0.65	0.49		0.61	-0.1	-0.31
Net Invested Capital	0.9	0.81	0.77	0.47	0.65	0.58	0.69	0.96	0.69	0.58	0.76	0.7	0.68	0.77	0.88	0.8	0.8	-0.74	0.84	0.81	0.81	0.26	0.61		0.05	-0.25
Net Working Capital	0.22	0.39	-0.4	0.6	0.25	0.39	0.1	-0.04	0.28	-0.7	0.06	0.06	0.64	0.41	-0.09	-0.24	-0.06	0.45	0.08	0.31	-0.08	-0.67	-0.1	0.05		0.54
Capital Stock	0.04	0.14	-0.54	0.55	-0.04	0.06	-0.13	-0.29	0.1	-0.41	-0.09	-0.11	0.05	0.02	-0.49	-0.63	-0.46	0.61	-0.28	-0.17	-0.33	-0.11	-0.31	-0.25	0.54

Click cells to compare fundamentals

In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.

Competition

Predict Emergent Biosolutions

In accordance with the recently published financial statements, Emergent Biosolutions has a Beta of 1.574. This is 83.02% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.

Emergent Beta Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Emergent Biosolutions' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Emergent Biosolutions could also be used in its relative valuation, which is a method of valuing Emergent Biosolutions by comparing valuation metrics of similar companies.

Emergent Biosolutions is currently under evaluation in beta category among its peers.

Emergent Biosolutions ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Emergent Biosolutions' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Emergent Biosolutions' managers, analysts, and investors.

Environmental

Governance

Social

Emergent Biosolutions Institutional Holders

Institutional Holdings refers to the ownership stake in Emergent Biosolutions that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Emergent Biosolutions' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Emergent Biosolutions' value.

		Shares
Two Sigma Investments Llc	2024-09-30	743.2 K
Assenagon Asset Management Sa	2024-09-30	741.6 K
Dimensional Fund Advisors, Inc.	2024-09-30	659.3 K
Jpmorgan Chase & Co	2024-06-30	649.5 K
Goldman Sachs Group Inc	2024-06-30	611 K
Geode Capital Management, Llc	2024-09-30	582 K
Two Sigma Advisers, Llc	2024-06-30	575.4 K
Bank Of America Corp	2024-06-30	554.9 K
Marshall Wace Asset Management Ltd	2024-06-30	542.8 K
Blackrock Inc	2024-06-30	3.8 M
Vanguard Group Inc	2024-09-30	3.4 M

As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Emergent Biosolutions will likely underperform.

Emergent Fundamentals

	Return On Equity	-0.35
	Return On Asset	-0.0422
	Profit Margin	(0.19) %
	Operating Margin	0.25 %
	Current Valuation	1.03 B
	Shares Outstanding	54.18 M
	Shares Owned By Insiders	2.15 %
	Shares Owned By Institutions	57.78 %
	Number Of Shares Shorted	6.95 M
	Price To Earning	1.67 X
	Price To Book	1.01 X
	Price To Sales	0.46 X
	Revenue	1.05 B
	Gross Profit	290.1 M
	EBITDA	(505.3 M)
	Net Income	(760.5 M)
	Cash And Equivalents	642.6 M
	Cash Per Share	7.28 X
	Total Debt	860.2 M
	Debt To Equity	0.56 %
	Current Ratio	3.92 X
	Book Value Per Share	9.40 X
	Cash Flow From Operations	(206.3 M)
	Short Ratio	5.21 X
	Earnings Per Share	(11.22) X
	Price To Earnings To Growth	1.55 X
	Target Price	12.0
	Number Of Employees	1.6 K
	Beta	1.57
	Market Capitalization	540.22 M
	Total Asset	1.82 B
	Retained Earnings	(21.8 M)
	Working Capital	28.2 M
	Current Asset	537.41 M
	Current Liabilities	99.61 M
	Net Asset	1.82 B

About Emergent Biosolutions Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Emergent Biosolutions's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emergent Biosolutions using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emergent Biosolutions based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Emergent Stock Analysis

When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC